StockData
Genprex, Inc. logo

Genprex, Inc. (GNPX) stock

GNPXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.67−0.04 (-2.34%)

Close on Nov 19, 2026Market cap $1.37MP/E –Yield –

Genprex free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Genprex's free cash flow for the twelve months ending Dec 31, 2022 was -$17.62M. For fiscal 2022 it was -$17.62M. The highest annual figure on record is -$1.25M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$17.62M–
FY2021Dec 31, 2021-$14.32M–
FY2020Dec 31, 2020-$13.95M–
FY2019Dec 31, 2019-$6.95M–
FY2018Dec 31, 2018-$6.87M–
FY2017Dec 31, 2017-$2.18M–
FY2016Dec 31, 2016-$1.25M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022-$4.55M–
Q3 FY2022Sep 30, 2022-$4.52M–
Q2 FY2022Jun 30, 2022-$4.48M–
Q1 FY2022Mar 31, 2022-$4.07M–
Q4 FY2021Dec 31, 2021-$3.23M–
Q3 FY2021Sep 30, 2021-$2.65M–
Q2 FY2021Jun 30, 2021-$2.88M–
Q1 FY2021Mar 31, 2021-$5.56M–
Q4 FY2020Dec 31, 2020-$3.90M–
Q3 FY2020Sep 30, 2020-$2.02M–
Q2 FY2020Jun 30, 2020-$3.51M–
Q1 FY2020Mar 31, 2020-$4.53M–
Q4 FY2019Dec 31, 2019-$1.75M–
Q3 FY2019Sep 30, 2019-$1.99M–
Q2 FY2019Jun 30, 2019-$1.57M–
Q1 FY2019Mar 31, 2019-$1.65M–
Q4 FY2018Dec 31, 2018-$2.07M–
Q3 FY2018Sep 30, 2018-$1.47M–
Q2 FY2018Jun 30, 2018-$3.12M–
Q1 FY2018Mar 31, 2018-$205.18K–
Q4 FY2017Dec 31, 2017-$211.46K–
Q3 FY2017Sep 30, 2017-$639.04K–
Q2 FY2017Jun 30, 2017-$674.92K–
Q1 FY2017Mar 31, 2017-$652.06K–
Q4 FY2016Dec 31, 2016-$853.62K–

More Genprex figures

See a number that looks wrong?